Ethics approval and consent to participate
The study protocol was reviewed and approved by the Ethics Committee of the Cancer Institute Hospital, Japanese Foundation for Cancer Research (approval number 2019-1073). Informed consent of using the clinical data for this study was obtained by the method of opt-out on the website from the patients according to instruction by the Ethics Committee of the Cancer Institute Hospital, Japanese Foundation for Cancer Research.
Consent for publication
Not applicable
Availability of data and materials
The datasets analyzed in the present study are not publicly available due to confidential clinical data for individual patients. However, the datasets are available from the corresponding author on reasonable request.
Competing interests
MN has received honoraria from Ono Pharmaceutical, Bristol Myers Squibb, Pfizer, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, Boehringer Ingelheim, MSD, Novartis; and received research funding from MSD, Novartis, Ono Pharmaceutical, Chugai Pharmaceutical, Bristol Myers Squibb, Taiho Pharmaceutical, Eli Lilly, AstraZeneca, Pfizer, Astellas; and had consulting/advisory roles for Novartis, Daiichi Sankyo Healthcare, Taiho Pharmaceutical, Bristol Myers Squibb, Boehringer Ingelheim, Ono Pharmaceutical, Eli Lilly, Chugai Pharmaceutical, AstraZeneca, Merck Serono, MSD, Pfizer.
AG has received honoraria from Ono Pharmaceutical, Bristol Myers Squibb, Pfizer, Chugai Pharmaceutical, Taiho Pharmaceutical, Daiichi Sankyo Healthcare, KYORIN Pharmaceutical, Accuray Japan, Boehringer Ingelheim, MSD, AstraZeneca, Kyowa Kirin, Otsuka Pharmaceutical, Eisai; and received research funding from Nippon Kayaku.
MS has received honoraria from Ono Pharmaceutical, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, Boehringer Ingelheim, MSD; and received research funding from Taiho Pharmaceutical, Chugai Pharmaceutical, Boehringer Ingelheim.
AH has received honoraria from Chugai Pharmaceutical, AstraZeneca, TAIHO, Lilly, Pfizer; and received research funding from Chugai Pharmaceutical, MSD Oncology, Abbvie, AstraZeneca, Loxo.
NY has received honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, MSD, Novartis, Bayer Yakuhin, and had consulting/advisory roles for Chugai Pharmaceutical.
KU has received honoraria from Ono Pharmaceutical, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly, AstraZeneca, Boehringer Ingelheim, and had consulting/advisory roles for AstraZeneca, Chugai Pharmaceutical.
SK has received honoraria from Chugai Pharmaceutical Co., Ltd., MSD K.K., Bristol-Myers Squibb, ONO Pharmaceutical , AstraZeneca (H)
All remaining authors report no conflict of interest.
Funding
The authors did not receive specific funding for this work.
Authors’ contributions
TT, SK, KU, and MN contributed substantially to the conception and design of the present study. TT, SK, HS, HY, YA, SU, TY, TH, KU, NY, AH, TH, MS, AG, and MN contributed substantially to the data analysis and interpretation. TT, SK, KU, MS, AG, and MN contributed substantially to drafting the manuscript.
All authors have approved the final manuscript.
Acknowledgements
The authors would like to thank NAI (www.nai.co.jp/) for the English language review.